Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$1.01 USD
-0.01 (-0.98%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $1.00 -0.01 (-0.99%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LCTX 1.01 -0.01(-0.98%)
Will LCTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LCTX
Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
LCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
U.S. Physical Therapy (USPH) Beats Q2 Earnings and Revenue Estimates
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Other News for LCTX
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
Lineage to Present at 2024 BIO International Convention
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
Buy Rating on Lineage Therapeutics Backed by Roche Collaboration and Solid Financials
Analysts Are Bullish on These Healthcare Stocks: Oncolytics Biotech (ONCY), Lineage Therap (LCTX)